Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This review proposes focusing on relationships between neuroactive steroids and psychiatric disorder symptoms, rather than relying on traditional disorder classifications, and reports no new clinical findings.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This study found that both finasteride and flutamide effectively reduce hirsutism in women with polycystic ovary syndrome or idiopathic hirsutism, but flutamide was more effective.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This review examines the physiological role of androgen conjugates in cutaneous androgen metabolism and questions their association with hirsutism, without presenting new clinical findings.

This study found that a combination therapy of Diane 35 with finasteride was more effective at reducing hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome after 3 months compared to Diane 35 alone.

This study found that women with androgenetic alopecia showed higher levels of certain hormones and lower levels of sex hormone-binding globulin than healthy controls, potentially linking these factors to alopecia severity.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

This article outlines management guidelines for androgenetic alopecia, highlighting that continued treatment with medications like finasteride or minoxidil typically halts progression and improves hair condition in most mild to moderate cases.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study found that both finasteride and flutamide effectively reduced hirsutism in women with polycystic ovary syndrome, decreasing the Ferriman-Gallwey score and hair diameter without significant side effects.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This article reviews expert opinions on combining pharmacologic treatments like minoxidil with hair transplantation, reporting improved hair density and regrowth in patients with partially functioning follicles.

This article reviews the genetic and psychological aspects of androgenetic alopecia in men and women, reporting no new clinical findings while emphasizing the broad impact of this hair loss condition.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This study found that freeze-dried finasteride nanoparticles improved the stability, solubility, and in vitro dissolution of the drug, indicating potential benefits for poorly water-soluble drugs.

This study reported that 6 months of finasteride treatment significantly improved idiopathic hirsutism in women, with benefits persisting 6 months post-treatment and no adverse reactions observed.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This study found that a low-dose intermittent finasteride regimen significantly reduced hirsutism scores in adolescent girls with PCOS or idiopathic hirsutism, with similar efficacy but potentially safer and less expensive than continuous administration.

This case report describes a 68-year-old woman with metastatic breast cancer who experienced significant improvement in visual acuity after stopping tamoxifen, which was associated with bilateral optic neuropathies.

This review discusses the latest understanding of androgenetic alopecia, including stem cell niches in hair follicles, and highlights emerging treatments like growth factors and platelet-rich plasma without new clinical findings.

This study found that tamsulosin, finasteride use, and aging are significantly associated with increased risk of intraoperative floppy iris syndrome during cataract surgery, while doxazosin does not appear to pose this risk.